Alembic Pharmaceuticals Gets USFDA Nod For Generic Eye Inflammation Treatment Emulsion

The approved ANDA is therapeutically equivalent to the reference listed drug product, Durezol ophthalmic emulsion, 0.05% of Sandoz Inc, it added

PTI

Updated on: 27 January 2026 2:21 pm

Alembic Pharmaceuticals Gets USFDA Nod For Generic Eye Inflammation Treatment Emulsion Photo: Moneycontrol

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of Difluprednate ophthalmic emulsion used to treat eye inflammation and pain due to surgery.

The approval granted by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) Difluprednate ophthalmic emulsion of strength 0.05% Alembic Pharmaceuticals said in a regulatory filing.

Sun Pharma Gets DCGI Nod For Generic Weight-Loss Drug Amid Patent Fight With Novo Nordisk

BY Outlook Business Desk

1 January 2026

Get the latest issue of Outlook Business

Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery and also indicated for the treatment of endogenous anterior uveitis, a type of disorder of the eye.